Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer

Clinical trial NCT05910398 · RECRUITING

Trial details

NCT number: NCT05910398
Sponsor: RenJi Hospital
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Breast Cancer Invasive

Start date: 2023-06-01
Primary completion: 2030-04-01
Enrollment: 488

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.